Drugs / GL-2045
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07605845 | Apr 2026 → Dec 2027 expected | thrombocytopenia due to immune destruction | Gliknik Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-02-19 | Gliknik Inc. | Gliknik to Receive $15 Million Milestone Payment from Pfizer Inc. Following Clinical Progress with PF-06755347, Previously Known as GL-2045 gliknik.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GL-2045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07605845 ↗ |
| Route | Subcutaneous | “Participants will receive GL-2045 by SC injection during the treatment period.” NCT07605845 ↗ |